Curaleaf Holdings (CURLF) Depreciation & Amortization (CF) (2019 - 2024)
Curaleaf Holdings (CURLF) posted quarterly Depreciation & Amortization (CF) of $73.1 million for Q4 2024, up 42.3% year-on-year from $51.4 million in Q1 2024, and up 33.88% on a QoQ basis from $54.6 million in Q3 2024.
Curaleaf Holdings (CURLF) Depreciation & Amortization (CF) (2019 - 2024) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Depreciation & Amortization (CF) for 6 consecutive years, with $73.1 million the latest figure, recorded in Q4 2024.
- Quarterly Depreciation & Amortization (CF) rose 42.3% year-over-year to $73.1 million in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $73.1 million (down 31.02% YoY) and the FY2025 annual result came in at $196.6 million, down 15.06% from the prior year.
- Depreciation & Amortization (CF) advanced to $73.1 million in Q4 2024 per CURLF's latest filing, from $54.6 million in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for CURLF reached as high as $73.1 million in Q4 2024 and fell as low as $14.9 million in Q1 2020.
- A 5-year average of $36.4 million and a median of $33.7 million in 2021 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2021 — Depreciation & Amortization (CF) soared 86.24% — and 2022, when it decreased 19.13%.
- Year by year, Depreciation & Amortization (CF) stood at $20.2 million in 2020, then grew by 25.47% to $25.4 million in 2021, then jumped by 73.66% to $44.1 million in 2022, then climbed by 16.55% to $51.4 million in 2023, then jumped by 42.3% to $73.1 million in 2024.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $73.1 million, $54.6 million, and $51.4 million for Q4 2024, Q3 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 73.12 Mn |
| Dec 31, 2024 | 73.12 Mn |
| Sep 30, 2024 | 54.61 Mn |
| Sep 30, 2024 | 54.61 Mn |
| Dec 31, 2023 | 51.38 Mn |
| Dec 31, 2023 | 51.38 Mn |
| Sep 30, 2023 | 47.28 Mn |
| Sep 30, 2023 | 47.28 Mn |
| Dec 31, 2022 | 44.09 Mn |
| Dec 31, 2022 | 44.09 Mn |
| Sep 30, 2022 | 28.23 Mn |
| Sep 30, 2022 | 28.23 Mn |
| Jun 30, 2022 | 42.82 Mn |
| Jun 30, 2022 | 42.82 Mn |
| Mar 31, 2022 | 40.84 Mn |
| Mar 31, 2022 | 40.84 Mn |
| Dec 31, 2021 | 25.39 Mn |
| Dec 31, 2021 | 25.39 Mn |
| Sep 30, 2021 | 34.91 Mn |
| Sep 30, 2021 | 34.91 Mn |